9th 3月 2022
Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director
22nd 2月 2022
Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)
15th 2月 2022
Newton Biocapital launches a new fund with initial capital commitments of EUR 50 million and target size of EUR 150 million.
13th 1月 2022
Epics Therapeutics Initiates First-in-Human Studies with EP282, an oral Investigational Drug for the treatment of gastrointestinal inflammatory disorders and cancer